Reportlinker Adds Infectious Disease Treatments: Global Markets

NEW YORK, May 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Infectious Disease Treatments: Global Markets

http://www.reportlinker.com/p0196568/Infectious-Disease-Treatments-Global-Markets.html

THIS REPORT

Provide global and U.S. infectious disease expenditures for 2008 and forecasts for those markets, with compound annual growth rates (CAGRs), through 2014.

Focus on the most prevalent diseases, including AIDS, HIV, Hepatitis A, Hepatitis B, and Hepatitis C, and will delve into other threats, such as staph infections, antibiotic-resistant infections, and influenza

Examine the vaccine industry, the newest profitable business model

Report on global and U.S. disease strategies.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

INTENDED AUDIENCE 2

METHODOLOGIES AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED BCC REPORTS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY 4

SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASE TREATMENTS, THROUGH 2014 ($ BILLIONS) 5

SUMMARY FIGURE GLOBAL MARKET FOR INFECTIOUS DISEASE TREATMENTS, 2008-2014 ($ BILLIONS) 5

Chapter-3: OVERVIEW

TABLE 1 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2006 (NUMBER OF CASES, ANNUALLY) 6

TABLE 1 (CONTINUED) 7

HISTORICAL IMPACT OF INFECTIOUS DISEASES 7

LINKING INFECTIOUS DISEASE TO CANCER 8

TRANSMISSION OF INFECTIOUS DISEASES 8

TREATMENTS FOR INFECTIOUS DISEASES 8

PREVENTION 8

VACCINATION 9

FIGURE 1 PERCENT OF PREVENTABLE CHILDHOOD DEATHS WITH VACCINATION, 2002 (%) 9

FIGURE 1 (CONTINUED) 10

TABLE 2 MAJOR MANUFACTURERS OF VACCINES FOR INFECTIOUS DISEASES, 2008 10

TABLE 3 ESTIMATED VACCINE SALES FOR INFECTIOUS DISEASES, BY MANUFACTURER, 2008 (%/$ MILLIONS) 11

TABLE 4 PROJECTED SALES OF VACCINES TO TREAT INFECTIOUS DISEASES WORLDWIDE, THROUGH 2014 ($ BILLIONS) 12

TABLE 5 SELECTED TREATMENT MODALITIES, BY DISEASE AND TYPE OF PRODUCT 12

MONITORING AND SURVEILLANCE 13

CURRENT IMPACT OF INFECTIOUS DISEASES 13

TABLE 6 TOP 10 CAUSES OF DEATH, BY INCOME GROUP, 2004 (%) 13

TABLE 6 (CONTINUED) 14

ANTIBIOTIC-RESISTANT ORGANISMS 14

IMPLICATIONS OF CLIMATE-CHANGE ON INFECTIOUS DISEASES 14

KEY DRIVERS OF INFECTIOUS DISEASE PRODUCT MARKET 15

KEY OBSTACLES IN THE INFECTIOUS DISEASE PRODUCT MARKET 15

OPPORTUNITIES TO FIGHT INFECTIOUS DISEASES 16

OPPORTUNITIES TO FIGHT … (CONTINUED) 17

Chapter-4: THE GLOBAL STATE OF INFECTIOUS DISEASE CONTROL AND TREATMENT

FACTORS IN THE EMERGENCE OF INFECTIONS 18

HUMAN DEMOGRAPHICS AND BEHAVIOR 18

TECHNOLOGY 18

ECONOMIC DEVELOPMENT AND LAND USE 19

INTERNATIONAL TRAVEL 19

MICROBIAL ADAPTATION 19

TABLE 7 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL 20

PUBLIC HEALTH MEASURES 20

GLOBAL IMPLICATIONS OF INFECTIOUS DISEASES 20

REGIONAL TRENDS 21

Sub-Saharan Africa 21

Asia and the Pacific 21

The Former Soviet Union and Eastern Europe 21

Latin America 21

Middle East and North Africa 21

Western Europe 22

GLOBAL ECONOMIC, SOCIAL, AND POLITICAL IMPACT 22

ECONOMIC COSTS 22

SOCIAL COSTS 23

POLITICAL IMPACT 23

IMPLICATIONS OF INFECTIOUS DISEASE IN THE U.S. 23

HIV/AIDS 23

HEPATITIS C 24

TUBERCULOSIS 24

INFLUENZA 24

ANTIBIOTIC-RESISTANT PATHOGENS 24

FOOD-BORNE ILLNESSES 24

INFECTIOUS DISEASES ACQUIRED OUTSIDE OF THE U.S. 25

EMERGING INFECTIOUS DISEASES 25

EMERGING BACTERIAL INFECTIOUS DISEASES 25

EMERGING VIRAL INFECTIOUS DISEASES 25

Metapneumoviruses 26

Henipavirus—Nipah, Hendra 26

PRION DISEASE 26

CREATING TREATMENTS FOR INFECTIOUS DISEASE 27

CREATING DRUG TREATMENTS 27

TABLE 8 PROCESS OF CREATING DRUG TREATMENTS 27

TABLE 8 (CONTINUED) 28

CREATING VACCINES 29

Creating Vaccines (Continued) 30

TABLE 9 TOP FIVE VACCINE-PRODUCING COMPANIES, 2009 31

ACQUISITIONS AMONG MANUFACTURERS OF INFECTIOUS DISEASE PRODUCTS 31

TABLE 10 SELECTED ACQUISITIONS AMONG INFECTIOUS DISEASE DRUG AND VACCINE MANUFACTURERS, 2006-2010 31

TABLE 10 (CONTINUED) 32

Chapter-5: BACTERIAL INFECTIOUS DISEASES

TABLE 11 SELECTED BACTERIAL INFECTIOUS DISEASES AND THE NUMBER OF CASES IN HUMANS 33

TABLE 11 (CONTINUED) 34

TABLE 12 PROJECTED MARKET FOR ANTIBACTERIAL TREATMENTS THROUGH 2014 ($ MILLIONS) 34

THE GLOBAL ANTIBACTERIAL DRUG MARKET 35

TREATMENTS 35

FIGURE 2 LEADING MANUFACTURERS OF ANTIBACTERIAL DRUGS, WITH APPROXIMATE MARKET SHARE, 2008 (%) 35

FIGURE 2 (CONTINUED) 36

TABLE 13 MAJOR MANUFACTURERS OF ANTIBACTERIALS AND THEIR PRODUCTS, 2009 36

MAJOR INFECTIOUS BACTERIAL DISEASES 37

BACTERIAL DIARRHEAL DISEASES 37

Cholera 37

Frequency 37

Treatment 38

Clostridium Difficile 38

Treatments under Development 38

Campylobacter 39

Treatment 39

EMERGING FOOD-BORNE/WATER-BORNE ILLNESSES 39

TABLE 14   CURRENTLY AVAILABLE TREATMENTS FOR SALMONELLA AND THEIR MANUFACTURERS 40

HAEMOPHILUS INFLUENZAE B (HIB) 41

Vaccination 41

TABLE 15 PROJECTED MARKET FOR HIB VACCINE, THROUGH 2014 ($ MILLIONS) 42

PNEUMONIA 42

Current Treatment 42

Vaccines 42

TABLE 16 PROJECTED REVENUES FROM VACCINES AND MEDICATIONS TO TREAT PNEUMONIA, THROUGH 2014 ($ MILLIONS) 43

SEXUALLY TRANSMITTED DISEASES 43

Chlamydia 43

TABLE 17 PRIMARY ANTIBIOTICS TO TREAT CHLAMYDIA 44

Emerging Treatment 44

Gonorrhea 44

TABLE 18 PRIMARY ANTIBIOTICS TO TREAT GONORRHEA 45

Emerging Treatment 45

Syphilis 45

Chancroid 46

STAPHYLOCOCCAL INFECTIONS 46

Emerging Treatments 47

Dalbavancin 47

Telavancin 47

Oritavancin 47

Ceftobiprole 48

Ceftaroline 48

TUBERCULOSIS 48

TABLE 19 NUMBER OF CASES OF TB ANNUALLY, BY COUNTRY, 2007 49

Frequency 49

United States 49

European Region 50

Drug-resistant Strains 50

Current Treatments 50

TABLE 20 PROJECTED GLOBAL REVENUES FOR TB DRUGS, THROUGH 2014 ($ MILLIONS) 51

TABLE 21 CURRENTLY AVAILABLE TREATMENTS FOR TB AND THEIR MANUFACTURERS 51

Emerging Treatments 51

URINARY TRACT INFECTIONS 52

TABLE 22 CURRENTLY AVAILABLE TREATMENTS FOR UTIS AND THEIR MANUFACTURERS 53

EMERGING TREATMENTS 53

Bacterial Interference 53

Bacteriophage Therapy 53

Bacteriophage Therapy (Continued) 54

Bacterial Vaccines 55

Cationic Peptides 55

Cyclic D,L-a-Peptides 56

Chapter-6: FUNGAL INFECTIOUS DISEASES

OPPORTUNISTIC FUNGAL INFECTIONS 57

PRIMARY FUNGAL INFECTIONS 57

FUNGAL INFECTIOUS DISEASES 58

TABLE 23 PROJECTED COST OF ANTIFUNGAL AGENTS TO TREAT FUNGAL INFECTIONS, THROUGH 2014 ($ BILLIONS) 58

FIGURE 3 MARKET SHARE OF COMPANIES INVOLVED IN THE TREATMENT OF FUNGAL INFECTIONS, 2009 (%) 59

CANDIDIASIS 59

Causes of Candidiasis 60

Frequency 60

Treatment 61

TABLE 24 CURRENT MEDICATIONS FOR CANDIDIASIS, 2009 61

TABLE 24 (CONTINUED) 62

Future Market 62

ASPERGILLOSIS 62

TABLE 25 CURRENT MEDICATIONS FOR ASPERGILLOSIS, 2009 63

COCCIDIOIDOMYCOSIS 63

Frequency 63

Treatment 64

TABLE 26 CURRENT MEDICATIONS FOR COCCIDIODOMYCOSIS, 2009 64

CRYPTOCOCCOSIS 64

Frequency 65

Treatment 65

TABLE 27 CURRENT MEDICATIONS FOR CRYPTOCOCCOSIS, 2009 65

MUCORMYCOSIS 65

Frequency 66

Treatment 66

TABLE 28 CURRENT MEDICATIONS FOR MUCORMYCOSIS, 2009 66

PARACOCCIDIOIDOMYCOSIS 67

Frequency 67

Treatment 67

TABLE 29 CURRENT MEDICATIONS FOR PARACOCCIDIOIDOMYCOSIS, 2009 67

PNEUMOCYSTIS CARINII 68

Frequency 68

Treatment 68

TABLE 30 CURRENT MEDICATIONS FOR PNEUMOCYSTIS CARNII, 2009 69

SPOROTYRICHOSIS 69

Treatment 69

TABLE 31 CURRENT MEDICATIONS FOR SPOROTYRICHOSIS, 2009 69

TRICHOSPORON INFECTIONS 70

Frequency 70

Treatment 70

TABLE 32 CURRENT MEDICATIONS FOR TRICHOSPORON INFECTIONS, 2009 70

ZYGOMYCOSIS 71

Frequency 71

Treatment 71

TABLE 33 CURRENT MEDICATIONS FOR ZYGOMYCOSIS, 2009 71

Chapter-7: VIRAL INFECTIOUS DISEASE

MAJOR DISEASES 72

RESEARCH FUNDING 72

TABLE 34 GLOBAL PROJECTIONS FOR VIRAL INFECTIOUS DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS) 73

HIV/AIDS 73

TABLE 35 PROJECTED GLOBAL MARKET FOR HIV DRUGS, THROUGH 2014 ($ MILLIONS) 74

SHIFTING PRIORITIES 74

TABLE 36 10 LEADING GLOBAL HIV MANUFACTURERS, 2010 74

FIGURE 4 MARKET SHARE FOR TOP MANUFACTURERS OF HIV TREATMENTS, 2009 (%) 75

EMERGING TREATMENTS 76

Gilead Sciences 76

Merck 76

ViiV Healthcare 76

Tibotec 76

TMC 278 77

COMMON PEDIATRIC VIRAL INFECTIONS 77

POLIOMYELITIS 77

DIPHTHERIA, TETANUS, PERTUSSIS (DTP) 78

TABLE 37 PROJECTIONS FOR DTP, POLIO, HIB COMBINATION VACCINE SALES, THROUGH 2014 ($ MILLIONS) 79

MEASLES, MUMPS, RUBELLA 79

Measles 79

Mumps 80

Rubella 80

TABLE 38 PROJECTED GLOBAL REVENUES FROM MMR VACCINE, THROUGH 2014 ($ MILLIONS) 81

CROUP 81

OTITIS MEDIA (EAR INFECTIONS) 81

Causes of Otitis Media 82

Treatment 82

TABLE 39 PROJECTED COSTS OF OTITIS MEDIA TREATMENTS, THROUGH 2014 ($ MILLIONS) 82

Pharmacological Intervention 82

Surgical Intervention 83

TABLE 40 GLOBAL SURGICAL COSTS FOR MYRINGOTOMY IN PEDIATRIC PATIENTS, THROUGH 2014 ($ MILLIONS) 83

TABLE 41 GLOBAL SURGICAL COSTS FOR TONSILLECTOMY/ADENOIDECTOMY IN PEDIATRIC PATIENTS, THROUGH 2014 ($ MILLIONS) 84

INFLUENZA 84

INFLUENZA TREATMENTS 85

TABLE 42 PROJECTED GLOBAL MARKET FOR INFLUENZA TREATMENTS, THROUGH 2014 ($ MILLIONS) 85

FIGURE 5 ESTIMATED MARKET SHARE OF COMPANIES IN INFLUENZA TREATMENT MARKET, 2009 (%) 86

EMERGING TREATMENTS 86

HEPATITIS 87

TABLE 43 HEPATITIS CHARACTERISTICS, BY TYPE 87

TABLE 43 (CONTINUED) 88

TABLE 44 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2010 88

TABLE 44 (CONTINUED) 89

TABLE 45 PROJECTED MARKET FOR HEPATITIS MEDICATIONS AND VACCINES, THROUGH 2014 ($ MILLIONS) 90

HEPATITIS A 90

TABLE 46 PROJECTED REVENUE FROM HEPATITIS A VACCINATION AND TREATMENTS, THROUGH 2014 ($ MILLIONS) 91

HEPATITIS B 91

TABLE 47 PROJECTED REVENUE FROM HEPATITIS B VACCINATION AND TREATMENTS, THROUGH 2014 ($ MILLIONS) 92

Emerging Treatments 92

HEPATITIS C 92

TABLE 48 PROJECTED REVENUE FROM HEPATITIS C TREATMENTS, THROUGH 2014 ($ MILLIONS) 93

FIGURE 6 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%) 93

FIGURE 6 (CONTINUED) 94

Emerging Treatments 94

HERPES VIRUSES 94

TABLE 49 HERPES VIRUSES THAT INFECT HUMANS 94

TABLE 50 PROJECTED MARKET FOR HERPES SIMPLEX VIRUS MEDICATIONS, THROUGH 2014 ($ MILLIONS) 95

HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) 95

HERPES SIMPLEX VIRUS TYPE 2 (HSV-2) 95

Prevalence 96

Emerging Treatment 96

Chiron 96

GlaxoSmithKline 97

Xenova/GlaxoSmithKline 97

Avant Immunotherapeutics 97

EPSTEIN-BARR VIRUS 98

HUMAN HERPES VIRUS 6 98

HUMAN HERPES VIRUS 8 98

EMERGING HERPES TREATMENTS 98

NanoViricides, Inc. 98

Cytogenix 99

Alnylam Pharmaceuticals, Inc. 99

VARICELLA VIRUSES 99

CHICKENPOX 99

SHINGLES 100

TABLE 51 PROJECTED MARKET FOR VARICELLA VACCINES, THROUGH 2014 ($ MILLIONS) 101

ENTEROVIRUSES 101

COXSACKIE VIRUSES 101

CREUTZFELDT-JAKOB DISEASE (CJD) 102

EMERGING TREATMENTS 102

Quinacrine 102

Pentosan Polysulphate (PPS) 103

OPPORTUNISTIC VIRAL INFECTIONS 103

CYTOMEGALOVIRUS 103

Current Treatments 104

TABLE 52 CURRENT TREATMENT OPTIONS FOR CMV, 2009 104

KAPOSI'S SARCOMA (KS) 104

HEMORRHAGIC FEVERS 105

ARENAVIRUSES 106

BUNYAVIRUSES 106

FILOVIRUSES 106

FLAVIVIRUSES 107

Frequency 107

Current Treatment 108

HUMAN PAPILLOMAVIRUS (HPV) 108

TREATMENT 108

TABLE 53 PROJECTED MARKET FOR HPV TREATMENTS, THROUGH 2014 ($ MILLIONS) 109

EMERGING TREATMENTS 109

UPPER RESPIRATORY VIRUSES 109

COMMON COLD 109

SINUSITOSIS 110

RESPIRATORY SYNCYTIAL VIRUS (RSV) 110

TABLE 54 CURRENT TREATMENTS FOR RSV 111

TABLE 55 PROJECTED MARKET FOR RSV TREATMENTS, THROUGH 2014 ($ MILLIONS) 111

Emerging Treatments 112

Arrow Therapeutics 112

Alnylam Pharmaceuticals 112

AstraZeneca/MedImmune 112

ROTAVIRUS 113

GLOBAL IMPACT 114

TREATMENTS 114

ROTATEQ 114

ROTARIX 114

TABLE 56 GLOBAL REVENUES FOR PEDIATRIC ROTAVIRUS VACCINES, THROUGH 2014 ($ MILLIONS) 115

TABLE 57 GLOBAL ROTAVIRUS VACCINE SALES, BY MANUFACTURER, 2008 ($ MILLIONS/%) 115

Chapter-8: PARASITIC INFECTIOUS DISEASE

CAUSES OF PARASITIC DISEASE 116

MALARIA 116

TABLE 58 PROJECTED GLOBAL REVENUES FOR MALARIAL PREVENTION AND TREATMENT MEASURES, THROUGH 2014 ($ MILLIONS) 117

CAUSES OF MALARIA 118

MALARIAL TREATMENTS 118

TABLE 59 AVAILABLE DRUGS FOR THE TREATMENT OF MALARIA, 2009 118

Current Treatments 119

TABLE 60 PROJECTED GLOBAL REVENUE FROM MALARIAL TREATMENTS, THROUGH 2014 ($ MILLIONS) 119

Evolving Treatments 119

GlaxoSmithKline 120

Novartis 120

Pfizer 120

Sanofi-aventis 120

Sigma-Tau 120

MOSQUITO NETTING 120

TABLE 61 MOSQUITO NETTING DISTRIBUTED, 2006-2008 121

TABLE 62 PROJECTED SALES OF MOSQUITO NETTING TO GLOBAL RELIEF AGENCIES, THROUGH 2014 ($ MILLIONS) 121

NEGLECTED TROPICAL DISEASES 122

TABLE 63 NUMBER OF ANNUAL INFECTIONS FROM LEISHMANIASIS, ONOCHOCERCIASIS, AND SCHISTOMIASIS 122

TABLE 64 AVAILABLE TREATMENTS FOR THE MOST COMMON NEGLECTED TROPICAL DISEASES 123

LEISHMANIASIS 123

Current Treatment 124

Emerging Treatments 124

ONOCHOCERCIASIS 124

Treatment 125

SCHISTOMIASIS 125

Treatment 126

TRYPANOSOMIASIS 127

African Trypanosomiasis 127

Chagas Disease 127

TREATMENT 127

EVOLVING TREATMENTS 128

TABLE 65 AVAILABLE DRUGS FOR THE TREATMENT OF TRYPANOSOMIASIS, 2009 129

LYMPHATIC FILIARIASIS 129

Treatment 130

DENGUE 130

OPPORTUNITIES FOR TREATMENTS FOR PARASITIC INFECTIOUS DISEASES 130

MALARIA 130

Synthetic Artemisinin 131

Eurartesim 131

Coartem Pediatric Dispersible Tablet 132

Pyramax 132

Phase I Projects 132

Tafenoquine 132

Artemisone 133

Preclinical Investigations 133

OZ 439 133

MK 4815 134

Mirincamycin 134

DENGUE 134

Clone Technology 135

Nucleotide Deletion 135

Other Approaches 136

SCHISTOSOMIASIS 136

ONCHOCERCIASIS 136

Chapter-9: PATENT ANALYSIS

PATENT ANALYSIS 137

TABLE 66 INFECTIOUS DISEASE TREATMENT PATENTS, BY COMPANY, YEAR FILED, AND DISEASE, 2000-2010 138

TABLE 66 (CONTINUED) 139

TABLE 66 (CONTINUED) 140

TABLE 66 (CONTINUED) 141

TABLE 67   INFECTIOUS DISEASE TREATMENT PATENTS ISSUED BETWEEN JANUARY 2000 AND JANUARY 2010, BY MAJOR COMPANY 142

TABLE 68 INFECTIOUS DISEASE TREATMENT PATENTS, BY COUNTRY, 2000-2010 143

TABLE 69 PATENTS ISSUED FOR TREATMENT OF BACTERIAL DISEASE, 2000-2010 143

TABLE 70 PATENTS ISSUED FOR TREATMENT OF FUNGAL DISEASE, JANUARY 2000-JANUARY 2010 144

TABLE 71 PATENTS ISSUED FOR TREATMENT OF VIRAL DISEASE, JANUARY 2000-JANUARY 2010 144

TABLE 72 PATENTS ISSUED FOR TREATMENT OF PARASITIC DISEASE, JANUARY 2000- JANUARY 2010 145

Chapter-10: COMPANY DIRECTORY

AMYRIS BIOTECHNOLOGIES 146

BUSINESS OVERVIEW 146

ALNYLAM PHARMACEUTICALS 146

BUSINESS OVERVIEW 146

FINANCIALS 147

PRODUCTS 147

AR SCIENTIFIC 147

BUSINESS OVERVIEW 147

FINANCIALS 147

PRODUCTS 148

ASTRAZENECA 148

BUSINESS OVERVIEW 148

FINANCIALS 148

PRODUCTS 149

BAXTER INTERNATIONAL, INC. 149

BUSINESS OVERVIEW 149

FINANCIALS 149

PRODUCTS 150

BRISTOL-MYERS SQUIBB 150

BUSINESS OVERVIEW 150

FINANCIALS 150

PRODUCTS 151

CIPLA, LTD. 151

BUSINESS OVERVIEW 151

FINANCIALS 151

PRODUCTS 151

CRUCELL N.V. 152

BUSINESS OVERVIEW 152

FINANCIALS 153

PRODUCTS 153

CUBIST PHARMACEUTICALS 154

BUSINESS OVERVIEW 154

FINANCIALS 154

PRODUCTS 155

GILEAD SCIENCES, INC. 155

BUSINESS OVERVIEW 155

FINANCIALS 155

PRODUCTS 156

Other Products 157

GLAXOSMITHKLINE 158

BUSINESS OVERVIEW 158

FINANCIALS 158

PRODUCTS 159

HOLLY PHARMACEUTICALS 160

BUSINESS OVERVIEW 160

FINANCIALS 160

PRODUCTS 160

IPCA LABORATORIES 160

BUSINESS OVERVIEW 161

FINANCIALS 161

PRODUCTS 161

JOHNSON & JOHNSON 161

BUSINESS OVERVIEW 161

FINANCIALS 162

PRODUCTS 162

MANGALAM DRUGS & ORGANICS, LTD. 163

BUSINESS OVERVIEW 163

FINANCIALS 163

PRODUCTS 163

MERCK & CO. 164

BUSINESS OVERVIEW 164

FINANCIALS 164

PRODUCTS 165

NOVARTIS INTERNATIONAL AG 165

BUSINESS OVERVIEW 165

FINANCIALS 166

PRODUCTS 166

PFIZER 167

BUSINESS OVERVIEW 167

FINANCIALS 167

PRODUCTS 168

PIDI STANDARD 169

BUSINESS OVERVIEW 169

FINANCIAL 169

PRODUCTS 170

ROCHE 170

BUSINESS OVERVIEW 170

FINANCIALS 170

PRODUCTS 170

SANOFI-AVENTIS 171

SANOFI PASTEUR 171

BUSINESS OVERVIEW 171

FINANCIALS 172

PRODUCTS 173

SOLVAY PHARMACEUTICALS S.A. 173

BUSINESS OVERVIEW 174

FINANCIALS 174

PRODUCTS 175

VERTEX PHARMACEUTICALS 175

BUSINESS OVERVIEW 175

FINANCIALS 175

PRODUCTS 176

WYETH PHARMACEUTICALS (PFIZER, INC.) 176

BUSINESS OVERVIEW 176

FINANCIALS 177

PRODUCTS 177

To order this report:

Therapy Industry: Infectious Disease Treatments: Global Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo